跳至主要内容
临床试验/JPRN-UMIN000009250
JPRN-UMIN000009250已完成1 期

The clinical trial investigating the safety in the treatment of osteonecrosis of the femoral head with a local application of recombinant human bFGF gelatin hydrogel for bone regeneration and preventing the femoral head collapse. - The clinical application of recombinant human bFGF gelatin hydrogel for osteonecrosis of the femoral head.

Department of Orthopedic Surgery, Kyoto University Hospital0 个研究点目标入组 10 人开始时间: 2012年11月2日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with Osteonecrosis of the femoral head who had been operated of the affected femoral head. BMI over 30. Serious complications including uncontrolled diabetes, serious hypertension, severe heart diseases and severe pulmonary diseases etc. Malignancies treated within 5 years not including carcinoma in situ and intramucosal carcinoma. Judged inappropriate with the reason for mental disorder or mental status by the treating physician Active infection Under treating diabetic retinopathy including preproliferative diabetic retinopathy and proliferative diabetic retinopathy. Gelatin allergy Drug allergy considered not to be suitable with this study. receiving systemic corticosteroids over 10mg dosage of Prednisolone.

研究者

发起方
Department of Orthopedic Surgery, Kyoto University Hospital

相似试验